Comirnaty Evropska unija - slovenščina - EMA (European Medicines Agency)

comirnaty

biontech manufacturing gmbh - single-stranded, 5’-capped messenger rna produced using a cell-free in vitro transcription from the corresponding dna templates, encoding the viral spike (s) protein of sars-cov-2 - covid-19 virus infection - cepiva - comirnaty 30 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older.  comirnaty 30 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older.  comirnaty 10 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years.  comirnaty 3 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years.  comirnaty original/omicron ba. 1 (15/15 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older who have previously received at least a primary vaccination course against covid-19. comirnaty original/omicron ba. 4-5 (15/15 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older. comirnaty original/omicron ba. 4-5 (5/5 micrograms)/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty original/omicron ba. 4-5 (5/5 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years.  comirnaty original/omicron ba. 4-5 (1. 5/1. 5 micrograms)/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years.  comirnaty omicron xbb. 5 30 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older. comirnaty omicron xbb. 5 10 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty omicron xbb. 5 10 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty omicron xbb. 5 3 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years. uporaba tega cepiva mora biti v skladu z uradnimi priporočili.

Protopy Evropska unija - slovenščina - EMA (European Medicines Agency)

protopy

astellas pharma gmbh - takrolimus - dermatitis, atopic - drugi dermatološki preparati - zdravljenje zmernega do hudega atopičnega dermatitisa pri odraslih, ki se ne odzivajo ali ne prenašajo na konvencionalne terapije, kot so lokalni kortikosteroidi. zdravljenje zmernega do hudega atopičnega dermatitisa pri otrocih (starih 2 leti in več), ki se ni ustrezno odzvalo na običajne terapije, kot so lokalni kortikosteroidi. vzdrževanje zdravljenje zmerno do hudo atopijskega dermatitisa za preprečevanje rakete in podaljšanje flare-prosto časovnih presledkih v pri bolnikih z visoko frekvenco bolezni exacerbations (i. prisotnih 4 ali več-krat na leto), ki so imeli prvi odziv na največ 6 tednov zdravljenja dvakrat dnevno takrolimus mazila (lezije očiščeno, skoraj očiščeno ali rahlo vpliva).

Axumin Evropska unija - slovenščina - EMA (European Medicines Agency)

axumin

blue earth diagnostics ireland ltd - fluciclovine (18f) - prostatic neoplasms; radionuclide imaging - diagnostični radiofarmacevtiki - to zdravilo je samo za diagnostično uporabo. axumin je označen za positron emission tomografija (pet) slikanje za odkrivanje ponovitve raka na prostati pri moških odraslih z suma ponovitve, ki temelji na zvišan krvni prostato specifični antigen (psa) ravni po primarni kurativnega zdravljenja.

Artesunate Amivas Evropska unija - slovenščina - EMA (European Medicines Agency)

artesunate amivas

amivas ireland ltd - artesunate - malarija - antiprotozoals - artesunate amivas is indicated for the initial treatment of severe malaria in adults and children. upoštevati je treba uradne smernice za ustrezno uporabo proti malariji agenti.

Lodotra 5 mg tablete s prirejenim sproščanjem Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

lodotra 5 mg tablete s prirejenim sproščanjem

mundipharma gmbh - prednizon - tableta s prirejenim sproščanjem - prednizon 5 mg / 1 tableta - prednizon

Lodotra 2 mg tablete s prirejenim sproščanjem Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

lodotra 2 mg tablete s prirejenim sproščanjem

mundipharma gmbh - prednizon - tableta s prirejenim sproščanjem - prednizon 2 mg / 1 tableta - prednizon

Epclusa Evropska unija - slovenščina - EMA (European Medicines Agency)

epclusa

gilead sciences ireland uc - sofosbuvir, velpatasvir - hepatitis c, kronični - antivirusi za sistemsko uporabo - epclusa is indicated for the treatment of chronic hepatitis c virus (hcv) infection in patients 3 years of age and older (see sections 4. 2, 4. 4 in 5.

Harvoni Evropska unija - slovenščina - EMA (European Medicines Agency)

harvoni

gilead sciences ireland uc - ledipasvir, sofosbuvir - hepatitis c, kronični - antivirusi za sistemsko uporabo - harvoni is indicated for the treatment of chronic hepatitis c (chc) in adult and paediatric patients aged 3 years and above (see sections 4. 2, 4. 4 in 5. za virus hepatitisa c (hcv) genotip-specifična aktivnost glej točki 4. 4 in 5.

Mozobil Evropska unija - slovenščina - EMA (European Medicines Agency)

mozobil

sanofi b.v. - plerixafor - multiple myeloma; hematopoietic stem cell transplantation; lymphoma - immunostimulants, - mozobil je naveden v kombinaciji z granulocitne kolonije stimulirajoči faktor za povečanje mobilizacije krvotvornih matičnih celic v periferni krvi za zbiranje in nadaljnje avtologno presaditvijo pri bolnikih z limfomi in več mielom, katerih celic aktiviranje slabo.